Ocumetics Technology Corp. (TSXV: OTC) (OTCQB: OTCFF) (FRA: 2QBO) announced that its clinical facility in Mexico City has initiated patient recruitment for Group Two of its ongoing human clinical study for the Ocumetics Lens, a next-generation accommodating intraocular lens. The move marks a significant step forward in the company's clinical development program, which aims to provide an alternative to corrective lenses for patients seeking improved vision across multiple distances.
The Group Two study is designed to evaluate both safety and performance, specifically near and distance vision, building on the safety-focused Group One study that concluded in Fall 2025. The company reported that Group One outcomes met and exceeded expectations regarding safety, performance, and handling. As Group One patients reach their 12-month follow-up visits, longer-term data is being collected, providing valuable insights into the lens's durability and effectiveness.
Dean Burns, President and CEO of Ocumetics, expressed enthusiasm about the progress: "We are extremely excited to begin the process of moving into our larger Group Two study. Commencement of this study represents another important milestone in the continued clinical development of the Ocumetics Lens. Recruiting will be completed soon and we will schedule surgical dates shortly thereafter."
Group Two patients will receive the latest-generation Ocumetics Lens, which incorporates design advancements and will be implanted using an enhanced delivery system. This combination is expected to improve surgical outcomes and patient experiences. The Mexico City facility, which successfully performed the Group One surgeries, is actively identifying and recruiting eligible patients for the upcoming Fall 2026 surgeries.
The Ocumetics Lens is designed to fit within the eye's natural lens compartment and utilize the eye's natural muscle activity to shift focus from distance to near, potentially eliminating the need for glasses or contact lenses. This technology represents a paradigm shift in intraocular lens design, offering a dynamic solution that mimics the natural accommodative function of the eye.
The initiation of Group Two is not only a clinical milestone but also a strategic move for Ocumetics as it progresses toward potential commercialization. With the global market for intraocular lenses projected to grow significantly, driven by an aging population and increasing prevalence of cataracts, the successful demonstration of safety and efficacy in this study could position Ocumetics as a leader in premium vision correction solutions.
Furthermore, the 12-month data from Group One will be crucial in assessing the long-term stability and performance of the lens. Positive results could accelerate regulatory approvals and attract potential partnerships or investment. The company's commitment to innovation is evident in its continuous refinement of the lens and delivery system, reflecting a dedication to addressing unmet needs in ophthalmology.
As Ocumetics advances its clinical program, the ophthalmic community watches closely. If successful, the Ocumetics Lens could offer an unprecedented solution for patients desiring independence from corrective eyewear, potentially transforming the standard of care in cataract and refractive surgery.
